title: Parasite vaccines--a reality?
abstract: Over the last decade, the anti-parasitics market has been the fastest growing sector of the overall $18 billion animal health market. While drugs for the treatment of parasites of livestock still dominate this sector and will continue to be developed or re-formulated, because of consumer demands for chemical-free food and of concerns regarding the environment and animal welfare there is a growing interest in the development of safe and effective vaccines. There is also a call for vaccines in the lucrative $3 billion-plus companion animal market. These demands for vaccines will add a greater impetus to an area that has seen tremendous success in the last 15 years. A number of anti-parasite vaccines have been developed, e.g. the recombinant 45w and EG95 oncosphere proteins against Taenia ovis and Echinococcus granulosis, respectively, and the Bm86 vaccine against Boophilus microplus. In addition, the cathepsin L vaccines against the liver fluke, Fasciola hepatica, and the H11 vaccine against Haemonchus contortus are progressing well. There are also many additional vaccine candidates for H. contortus and for other nematodes such as Ostertagia and Trichostrongylus spp. that may ultimately lead to broad-spectrum gastrointestinal worm vaccines. Live or attenuated-live vaccines are available for the control of avian coccidiosis, toxplasmosis in sheep and anaplasmosis in cattle, although molecular vaccines against protozoans are still proving elusive. The wealth of information in genomics, proteomics and immunology that has been forthcoming together will new methods of vaccine production and delivery should see many new vaccines reach the marketplace in the near future.
authors.affiliation: School of Biotechnology, Dublin City University, Dublin 9, Ireland. john.dalton@dcu.ie
authors.forename: J P
authors.initials: JP
authors.lastname: Dalton
authors.forename: G
authors.initials: G
authors.lastname: Mulcahy
mesh_terms: D000818:Animals; D000829:Animals, Domestic / Q000469:parasitology*; D056668:Cathepsin L; D002403:Cathepsins / Q000276:immunology; D003546:Cysteine Endopeptidases; D010273:Parasitic Diseases, Animal / Q000276:immunology* / Q000517:prevention & control; D016052:Protozoan Vaccines / Q000276:immunology* / Q000592:standards; D014611:Vaccination / Q000662:veterinary*; D015164:Vaccines, Inactivated / Q000276:immunology / Q000592:standards
chemical_list: D016052:Protozoan Vaccines; D015164:Vaccines, Inactivated; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D056668:Cathepsin L